people's pharmacy semaglutide BOOST BUNDLE – Paul's We're expanding access to compounded

$153.750 PUM: $ 443.81 g $ 54.750 PUM: $ 2,607.14 BOL $ 54.600 PUM: $ 1,365.00 g $ 63.700 PUM: $ 1637.00 ML TECNOQUIMICAS S.A

It is not FDA-approved in the same way that Ozempic or Wegovy are

Current ESC guidelines assign a Class I recommendation to GLP-1RAs for patients with type 2 diabetes and established cardiovascular disease

Implications for insurers Insurers should consider the impact of AOMs across their business: Assess how AOMs may impact protection, morbidity, and longevity experience Review trend assumptions to identify whether changes are needed Establish processes to keep on top of this fast-moving space Consider new lapse risks Assess how AOMs might affect underwriting and claims Insured impacts and reviewing trend assumptions Insurers should consider adjustments to their specific mortality and morbidity improvement assumptions to reflect AOMs

Safety Considerations GLP-1 injections have well-documented safety profiles

Recent regulatory reviews by the MHRA and European Medicines Agency have assessed reports of psychiatric adverse events with GLP-1 receptor agonists, but no causal link has been established